LawCrossing has introduced a newly updated comprehensive review database focused on BigLaw summer associate programs, providing law students and early-career professionals with a centralized resource ...

(RTTNews) - Organon (OGN) announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for NEXPLANON (etonogestrel implant). NEXPLANON is ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Agios Pharmaceuticals, Inc.’s (NASDAQ: AGIO) Aqvesme (mitapivat), an oral pyruvate kinase (PK) activator, for anemia in adults with ...

CNBC ranks the 75 most valuable college athletic programs. The programs are worth a combined $51.22 billion, 13% more than the top 75 in last year's rankings. Earlier this month the University of Utah ...

MINOT — Recently I wrote about Thread, which for years was a start-up darling based in Grand Forks that was showered with state and federal tax dollars. The company, which is now in arrears on its ...

Frederick L. Locke, MD, discusses the 2025 removal of the REMS program for CAR T-cell therapy and the resulting improvements to patient access. Frederick L. Locke, MD, chair of the Department of Blood ...

In an interview with Targeted Oncology, Frederick L. Locke, MD, discussed how the elimination of the REMS program for CAR T-cell therapy came about and what effects he hopes this will have on patient ...

Introduction: Mavacamten is a first-in-class cardiac myosin inhibitor approved by the FDA for the treatment of adults with symptomatic New York Heart Association (NYHA) class II–III obstructive ...

WASHINGTON — The Department of Army today announced the launch of the Janus Program, a next-generation nuclear power program that will deliver resilient, secure, and assured energy to support national ...

The REMS program for vandetanib in the treatment of patients with medullary thyroid cancer has been removed by the FDA. The FDA has terminated its Risk Evaluation and Mitigation Strategies (REMS) ...

Vandetanib (Caprelsa, Sanofi), a thyroid cancer medication, is an oral tyrosine kinase inhibitor that targets cell receptors involved in RET, VEGFR and EGFR signaling. The FDA has removed the Risk ...